Octreotide Injection

342 interactions 555 cited references
Also sold as: Bynfezia Bynfezia® Mycapssa Sandostatin Sandostatin® Sandostatin® LAR Depot
About Octreotide Injection

Octreotide immediate-release injection is used to decrease the amount of growth hormone (a natural substance) produced by people with acromegaly (condition in which the body produces too much growth hormone, causing enlargement of the hands, feet, and facial features; joint pain; and other symptoms) who cannot be treat… Read the full Octreotide Injection drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 10, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Dronedarone Levoketoconazole Levomethadyl Mesoridazine Pimozide Ziprasidone
13 Contraindicated 325 Major 4 Moderate
All (342) Contraindicated (13) Major (325) Moderate (4)

Major

Octreotide Injection Axitinib Inlyta Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Azimilide An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Azithromycin AzaSite An increased risk of QT interval prolongation Details Octreotide Injection Bedaquiline Sirturo Increased risk of QT interval prolongation Details Octreotide Injection Bosutinib Bosulif Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Bretylium An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Brigatinib Alunbrig Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Buprenorphine Belbuca An increased risk of QT interval prolongation Details Octreotide Injection Calcium Carbonate Alka-Mints Decreased octreotide bioavailability Details Octreotide Injection Calcium Silicate Decreased octreotide bioavailability Details Octreotide Injection Canagliflozin Invokana An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Ceritinib Zykadia An increased risk of QT interval prolongation Details Octreotide Injection Chloral Hydrate An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Chloroquine Aralen® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Chlorpromazine An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Chlorpropamide Diabinese® An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Cimetidine Tagamet Decreased octreotide bioavailability Details Octreotide Injection Ciprofloxacin An increased risk of QT interval prolongation and torsade de pointes Details Octreotide Injection Citalopram Celexa An increased risk of QT interval prolongation Details Octreotide Injection Clarithromycin Biaxin Increased risk of QT interval prolongation Details Octreotide Injection Clindamycin ANTIROBE Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Clofazimine An increased risk of QT interval prolongation Details Octreotide Injection Clomipramine Anafranil An increased risk of QT interval prolongation Details Octreotide Injection Clothiapine Increased risk of cardiac arrhythmias Details Octreotide Injection Clozapine Clozaril Increased risk of QT interval prolongation Details Octreotide Injection Cobimetinib Cotellic Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Colchicine Colcrys Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Conivaptan Vaprisol Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Copper Cu 64 Dotatate Decreased copper Cu 64 dotatate efficacy Details Octreotide Injection Crizotinib Xalkori An increased risk of QT interval prolongation Details Octreotide Injection Cyclobenzaprine Amrix An increased risk of QT interval prolongation Details Octreotide Injection Cyclosporine Atopica Reduced cycloSPORINE exposure and reduced efficacy of cycloSPORINE Details Octreotide Injection Dabrafenib Tafinlar An increased risk of QT interval prolongation Details Octreotide Injection Dapagliflozin Farxiga An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Dasatinib Phyrago An increased risk of QT interval prolongation Details Octreotide Injection Degarelix Firmagon Increased risk of QT interval prolongation Details Octreotide Injection Delamanid Increased risk of QT interval prolongation Details Octreotide Injection Desflurane Suprane An increased risk of QT interval prolongation Details Octreotide Injection Desipramine Norpramin An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Desogestrel Decreased bioavailability and decreased efficacy of combined oral contraceptives or increased breakthrough bleeding Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.